How CELLINK is making cancer models more accurate and reproducible
Today, cancer research relies primarily on 2D cultures and animal models. These methods have their limitations – almost 95% of drug candidates fail in clinical trials despite showing promising results in preclinical trials. While they’re an important source of in vivo information, today’s preclinical models can’t mimic the complex processes of the human tumor microenvironment (TME).
With further development, TumourPrint can:
The TumourPrint project is being funded in part by the European Union.
Project Number: 829846
Project Acronym: TUMOURPRINT
Project title: High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research